Letter to the Editor Open Access
Volume 3 | Issue 2 | DOI: https://doi.org/10.33696/Pharmacol.3.024

Remdesivir in COVID-19 Patients with End Stage Renal Disease on Hemodialysis

  • 1Division of Hospital Medicine, The Miriam Hospital, Providence, Rhode Island, USA
  • 2Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA
+ Affiliations - Affiliations

Corresponding Author

Vijairam Selvaraj, vijairam.selvaraj@lifespan.org

Received Date: April 03, 2021

Accepted Date: May 03, 2021


To date, only glucocorticoids have been shown to reduce mortality in COVID-19. Use of remdesivir was associated with reduced length of stay in hospitalized COVID-19 patients. A deadly second wave in Asian countries has caused increased demand and usage of remdesivir in these countries. However, there is limited data about its efficacy in patients with severe renal dysfunction or end-stage renal disease on dialysis.


Author Information X